Biotech News
Related news
OCSOculis2026-05-05 08:00 EST
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
PRQRProQR Therapeutics2026-05-04 12:00 EST
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
SGHTSight Sciences2026-04-01 20:05 EST
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
OTLKOutlook2026-04-21 13:05 EST
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-08-06 20:05 EST
Oculis Reports Q2 2026 Financial Results and Provides Company Update
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OCSOculis2026-07-08 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Stock data
- Close
- 12.38 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States